{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:31:51Z","timestamp":1793658711094,"version":"4.5.1"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.virol.2025.110677","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T15:10:06Z","timestamp":1756825806000},"page":"110677","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Neutralizing monoclonal antibodies against dengue virus: a scoping review of preclinical and clinical development"],"prefix":"10.1016","volume":"612","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5765-533X","authenticated-orcid":false,"given":"Irene","family":"Terzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Dimitriadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melina","family":"Ntoga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasilios","family":"Petrakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioulia","family":"Dragoumani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filothei","family":"Markatou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros","family":"Rafailidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.virol.2025.110677_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002930","article-title":"Structural basis of differential neutralization of DENV-1 genotypes by an antibody that recognizes a cryptic epitope","volume":"8","author":"Austin","year":"2012","journal-title":"PLoS Pathog."},{"issue":"2","key":"10.1016\/j.virol.2025.110677_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000790","article-title":"Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification","volume":"6","author":"Balsitis","year":"2010","journal-title":"PLoS Pathog."},{"issue":"7446","key":"10.1016\/j.virol.2025.110677_bib3","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.virol.2025.110677_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006209","article-title":"Neutralization of antibody-enhanced dengue infection by VIS513, a pan serotype reactive monoclonal antibody targeting domain III of the dengue E protein","volume":"12","author":"Budigi","year":"2018","journal-title":"PLoS Neglected Trop. Dis."},{"issue":"11","key":"10.1016\/j.virol.2025.110677_bib5","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/s41577-023-00858-w","article-title":"Antiviral neutralizing antibodies: from in vitro to in vivo activity","volume":"23","author":"Burton","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.virol.2025.110677_bib6","first-page":"82","article-title":"Therapeutic monoclonal antibodies approved by FDA in 2016","volume":"6","author":"Cai","year":"2017","journal-title":"MOJ Immunol"},{"key":"10.1016\/j.virol.2025.110677_bib7","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1586\/14787210.2013.839941","article-title":"Therapeutic antibodies as a treatment option for dengue fever","volume":"11","author":"Chan","year":"2013","journal-title":"Expert Rev. Anti Infect. Ther."},{"issue":"1","key":"10.1016\/j.virol.2025.110677_bib8","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12985-017-0856-8","article-title":"Characterization and epitope mapping of dengue virus type 1 specific monoclonal antibodies","volume":"14","author":"Chen","year":"2017","journal-title":"Virol. J."},{"key":"10.1016\/j.virol.2025.110677_bib11","article-title":"A phase 2, randomized, Double-Blind, Placebo-Controlled, dose-ranging Study to compare the safety and efficacy of 3 dose levels of AV-1 in healthy adults challenged with a controlled human infection strain of DENV-3","year":"2025","journal-title":"Identifier: NCT06799741"},{"key":"10.1016\/j.virol.2025.110677_bib12","article-title":"Adaptive Dengue Antiviral Platform Trial (ADAPT)","year":"2025","journal-title":"Identifier: NCT06551844"},{"key":"10.1016\/j.virol.2025.110677_bib13","article-title":"Double-Blind, Placebo-Controlled, single ascending dose Study to determine the safety and pharmacokinetics of AV-1 in healthy Male and female adult subjects","year":"2020","journal-title":"Identifier: NCT04273217"},{"issue":"3","key":"10.1016\/j.virol.2025.110677_bib14","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/emboj.2011.439","article-title":"Structural insights into the neutralization mechanism of a higher primate antibody against dengue virus","volume":"31","author":"Cockburn","year":"2012","journal-title":"EMBO J."},{"key":"10.1016\/j.virol.2025.110677_bib15","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ijid.2023.06.021","article-title":"Monoclonal antibodies as COVID-19 prophylaxis therapy in immunocompromised patient populations","volume":"134","author":"Cowan","year":"2023","journal-title":"Int. J. Infect. Dis."},{"issue":"5","key":"10.1016\/j.virol.2025.110677_bib16","doi-asserted-by":"crossref","DOI":"10.1093\/immhor\/vlaf012","article-title":"In vitro and in vivo neutralization of Dengue virus by a single domain antibody","volume":"9","author":"Dahiya","year":"2025","journal-title":"ImmunoHorizons"},{"issue":"6","key":"10.1016\/j.virol.2025.110677_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001188","article-title":"In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection","volume":"5","author":"de Alwis","year":"2011","journal-title":"PLoS Neglected Trop. Dis."},{"issue":"1","key":"10.1016\/j.virol.2025.110677_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0016059","article-title":"A broadly flavivirus cross-neutralizing monoclonal antibody that recognizes a novel epitope within the fusion loop of E protein","volume":"6","author":"Deng","year":"2011","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.virol.2025.110677_bib19","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.cell.2015.07.005","article-title":"Molecular insight into dengue virus pathogenesis and its implications for disease control","volume":"162","author":"Diamond","year":"2015","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.virol.2025.110677_bib20","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01559-15","article-title":"Genotypic differences in dengue virus neutralization are explained by a single amino acid mutation that modulates virus breathing","volume":"6","author":"Dowd","year":"2015","journal-title":"mBio"},{"key":"10.1016\/j.virol.2025.110677_bib21","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.52384","article-title":"Broad neutralizing human antibodies against dengue virus identified by single b cell transcriptomics","volume":"8","author":"Durham","year":"2019","journal-title":"eLife"},{"key":"10.1016\/j.virol.2025.110677_bib22","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/s41591-019-0746-2","article-title":"Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor","volume":"26","author":"Dussupt","year":"2020","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.virol.2025.110677_bib23","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/emmm.201303404","article-title":"A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface","volume":"6","author":"Fibriansah","year":"2014","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.virol.2025.110677_bib24","doi-asserted-by":"crossref","first-page":"6341","DOI":"10.1038\/ncomms7341","article-title":"A highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins","volume":"6","author":"Fibriansah","year":"2015","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.virol.2025.110677_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009331","article-title":"Antibody affinity versus dengue morphology influences neutralization","volume":"17","author":"Fibriansah","year":"2021","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.virol.2025.110677_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/srep36339","article-title":"Genome-wide analyses reveal a highly conserved dengue virus envelope peptide which is critical for virus viability and antigenic in humans","volume":"6","author":"Fleith","year":"2016","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.virol.2025.110677_bib27","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/infdis\/jiw102","article-title":"Dengue viruses and lifelong immunity: reevaluating the conventional wisdom","volume":"214","author":"Forsey","year":"2016","journal-title":"J. Infect. Dis."},{"issue":"5","key":"10.1016\/j.virol.2025.110677_bib28","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01461-15","article-title":"A new quaternary structure epitope on dengue virus serotype 2 is the target of durable type-specific neutralizing antibodies","volume":"6","author":"Gallichotte","year":"2015","journal-title":"mBio"},{"issue":"1","key":"10.1016\/j.virol.2025.110677_bib29","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00380-16","article-title":"Epitope addition and ablation via manipulation of a dengue virus serotype 1 infectious clone","volume":"2","author":"Gallichotte","year":"2017","journal-title":"mSphere"},{"key":"10.1016\/j.virol.2025.110677_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006934","article-title":"Human dengue virus serotype 2 neutralizing antibodies target two distinct quaternary epitopes","volume":"14","author":"Gallichotte","year":"2018","journal-title":"PLoS Pathog."},{"issue":"16","key":"10.1016\/j.virol.2025.110677_bib31","doi-asserted-by":"crossref","first-page":"8947","DOI":"10.3390\/ijms22168947","article-title":"The role of Fc receptors on the effectiveness of therapeutic monoclonal antibodies","volume":"22","author":"Gogesch","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"22","key":"10.1016\/j.virol.2025.110677_bib32","doi-asserted-by":"crossref","first-page":"9422","DOI":"10.1073\/pnas.0703498104","article-title":"Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention","volume":"104","author":"Goncalvez","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.virol.2025.110677_bib33","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S1473-3099(24)00030-6","article-title":"An observer-blind, randomized, placebo-controlled, phase 1, single ascending dose study of dengue monoclonal antibody in healthy adults in Australia","volume":"24","author":"Gunale","year":"2024","journal-title":"Lancet Infect. Dis."},{"issue":"2","key":"10.1016\/j.virol.2025.110677_bib34","first-page":"156","article-title":"Designing a polytope for use in a broad-spectrum dengue virus vaccine","volume":"13","author":"Himmah","year":"2017","journal-title":"J Taibah Univ Med Sci"},{"issue":"6","key":"10.1016\/j.virol.2025.110677_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007836","article-title":"A broadly neutralizing germline-like human monoclonal antibody against dengue virus envelope domain III","volume":"15","author":"Hu","year":"2019","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.virol.2025.110677_bib36","doi-asserted-by":"crossref","first-page":"7813","DOI":"10.1038\/s41467-023-43399-5","article-title":"Adults on pre-exposure prophylaxis (Tenofovir-emtricitabine) have faster clearance of anti-HIV monoclonal antibody VRC01","volume":"14","author":"Huang","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.virol.2025.110677_bib37","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.4021","article-title":"Generation and characterization of cross neutralizing human monoclonal antibody against 4 serotypes of dengue virus without enhancing activity","volume":"5","author":"Injampa","year":"2017","journal-title":"PeerJ"},{"issue":"10","key":"10.1016\/j.virol.2025.110677_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0139741","article-title":"Characterization of a novel dengue serotype 4 virus-specific neutralizing epitope on the envelope protein domain III","volume":"10","author":"Ji","year":"2015","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.virol.2025.110677_bib39","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.92428","article-title":"Cross-reactive dengue human monoclonal antibody prevents severe pathologies and death from Zika virus infections","volume":"2","author":"Kam","year":"2017","journal-title":"JCI Insight"},{"issue":"6365","key":"10.1016\/j.virol.2025.110677_bib40","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1126\/science.aan6836","article-title":"Antibody-dependent enhancement of severe dengue disease in humans","volume":"358","author":"Katzelnick","year":"2017","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.virol.2025.110677_bib41","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.celrep.2018.10.031","article-title":"A combination of two human monoclonal antibodies prevents Zika virus escape mutations in non-human primates","volume":"25","author":"Keeffe","year":"2018","journal-title":"Cell Rep."},{"issue":"4","key":"10.1016\/j.virol.2025.110677_bib42","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1128\/JVI.02957-12","article-title":"Structure of a dengue virus envelope protein late-stage fusion intermediate","volume":"87","author":"Klein","year":"2013","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.virol.2025.110677_bib43","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-92403-9","article-title":"An affinity-matured human monoclonal antibody targeting fusion loop epitope of dengue virus with in vivo therapeutic potency","volume":"11","author":"Kotaki","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.virol.2025.110677_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2020.198278","volume":"294","author":"Kotaki","year":"2021","journal-title":"Virus Res."},{"issue":"10","key":"10.1016\/j.virol.2025.110677_bib45","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1002\/ppul.27041","article-title":"Monoclonal antibody therapies in respiratory syncytial virus prophylaxis\u2014an umbrella review","volume":"59","author":"Kuitunen","year":"2024","journal-title":"Pediatr. Pulmonol."},{"issue":"23","key":"10.1016\/j.virol.2025.110677_bib46","doi-asserted-by":"crossref","first-page":"12766","DOI":"10.1128\/JVI.01420-07","article-title":"Epitope determinants of a chimpanzee dengue virus type 4 (DENV-4)-neutralizing antibody and protection against DENV-4 challenge in mice and rhesus monkeys by passively transferred humanized antibody","volume":"81","author":"Lai","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2025.110677_bib47","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.str.2017.11.017","article-title":"Structural and functional characterization of a cross-reactive dengue virus neutralizing antibody that recognizes a cryptic epitope","volume":"26","author":"Li","year":"2018","journal-title":"Structure"},{"key":"10.1016\/j.virol.2025.110677_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007716","article-title":"Potent neutralizing antibodies elicited by dengue vaccine in rhesus macaque target diverse epitopes","volume":"15","author":"Li","year":"2019","journal-title":"PLoS Pathog."},{"issue":"12","key":"10.1016\/j.virol.2025.110677_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0145381","article-title":"The molecular engineering of an anti-idiotypic antibody for pharmacokinetic analysis of a fully human anti-infective","volume":"10","author":"Lim","year":"2015","journal-title":"PLoS One"},{"issue":"25","key":"10.1016\/j.virol.2025.110677_bib50","doi-asserted-by":"crossref","first-page":"6067","DOI":"10.1016\/j.cell.2021.11.009","article-title":"Human antibody C10 neutralizes by diminishing zika but enhancing dengue virus dynamics","volume":"184","author":"Lim","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.virol.2025.110677_bib51","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.virol.2022.09.007","article-title":"A human monoclonal antibody to neutralize all four serotypes of dengue virus derived from patients at the convalescent phase of infection","volume":"576","author":"Lu","year":"2022","journal-title":"Virology"},{"issue":"6","key":"10.1016\/j.virol.2025.110677_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2025.112534","article-title":"A two-component cocktail of engineered DIII nanoparticles elicits broadly neutralizing antibody responses against dengue virus in mice","volume":"28","author":"Mariano","year":"2025","journal-title":"iScience"},{"issue":"8","key":"10.1016\/j.virol.2025.110677_bib53","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1586\/14760584.2013.815412","article-title":"Dengue vaccines: recent developments, ongoing challenges and current candidates","volume":"12","author":"McArthur","year":"2013","journal-title":"Expert Rev. Vaccines"},{"issue":"9","key":"10.1016\/j.virol.2025.110677_bib54","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.1128\/JVI.78.9.4665-4674.2004","article-title":"Identification of chimpanzee Fab fragments by repertoire cloning and production of a full-length humanized immunoglobulin G1 antibody that is highly efficient for neutralization of dengue type 4 virus","volume":"78","author":"Men","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2025.110677_bib55","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.4049\/jimmunol.1200227","article-title":"Structural analysis of a dengue cross-reactive antibody complexed with envelope domain III reveals the molecular basis of cross-reactivity","volume":"188","author":"Midgley","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.virol.2025.110677_bib56","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/978-1-4614-7651-1_8","article-title":"Class II fusion proteins","volume":"790","author":"Modis","year":"2013","journal-title":"Adv. Exp. Med. Biol."},{"issue":"24","key":"10.1016\/j.virol.2025.110677_bib57","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","article-title":"A randomized, controlled trial of Ebola virus disease therapeutics","volume":"381","author":"Mulangu","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virol.2025.110677_bib58","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.antiviral.2017.05.007","article-title":"Preclinical evaluation of VIS513, a therapeutic antibody against dengue virus, in non-human primates","volume":"144","author":"Ong","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virol.2025.110677_bib59","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1099\/vir.0.006874-0","article-title":"On a mouse monoclonal antibody that neutralizes all four dengue virus serotypes","volume":"90","author":"Rajamanonmani","year":"2009","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.virol.2025.110677_bib60","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.virol.2021.03.013","article-title":"Diverse contributions of avidity to the broad neutralization of dengue virus by antibodies targeting the E dimer epitope","volume":"559","author":"Remmel","year":"2021","journal-title":"Virology"},{"issue":"11","key":"10.1016\/j.virol.2025.110677_bib61","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/s41590-018-0227-7","article-title":"Characterization of a potent and highly unusual minimally enhancing antibody directed against dengue virus","volume":"19","author":"Renner","year":"2018","journal-title":"Nat. Immunol."},{"issue":"4","key":"10.1016\/j.virol.2025.110677_bib62","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.cell.2017.04.024","article-title":"Recurrent potent human neutralizing antibodies to Zika virus in Brazil and Mexico","volume":"169","author":"Robbiani","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.virol.2025.110677_bib63","doi-asserted-by":"crossref","first-page":"11800","DOI":"10.1128\/JVI.05237-11","article-title":"A fusion-loop antibody enhances the infectious properties of immature flavivirus particles","volume":"85","author":"Rodenhuis-Zybert","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2025.110677_bib64","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/nri3014","article-title":"Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms","volume":"11","author":"Rothman","year":"2011","journal-title":"Nat. Rev. Immunol."},{"issue":"7545","key":"10.1016\/j.virol.2025.110677_bib65","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nature14130","article-title":"Recognition determinants of broadly neutralizing human antibodies against dengue viruses","volume":"520","author":"Rouvinski","year":"2015","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.virol.2025.110677_bib66","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3390\/antib12020036","article-title":"Complement activation by an anti-dengue\/Zika antibody with impaired Fc\u03b3 receptor binding provides strong efficacy and abrogates risk of antibody-dependent enhancement","volume":"12","author":"Sampei","year":"2023","journal-title":"Antibodies"},{"key":"10.1016\/j.virol.2025.110677_bib67","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1200195","article-title":"Dengue virus neutralizing antibody: a review of targets, cross-reactivity, and antibody-dependent enhancement","volume":"14","author":"Sarker","year":"2023","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.virol.2025.110677_bib68","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1080\/19420862.2016.1148850","article-title":"A bispecific antibody effectively neutralizes all four serotypes of dengue virus by simultaneous blocking virus attachment and fusion","volume":"8","author":"Shi","year":"2016","journal-title":"mAbs"},{"issue":"9","key":"10.1016\/j.virol.2025.110677_bib69","doi-asserted-by":"crossref","first-page":"6591","DOI":"10.1074\/jbc.M009483200","article-title":"High resolution mapping of the binding site on human IgG1 for Fc\u03b3 receptors and design of IgG1 variants with altered binding","volume":"276","author":"Shields","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.virol.2025.110677_bib70","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000823","article-title":"The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1","volume":"6","author":"Shrestha","year":"2010","journal-title":"PLoS Pathog."},{"issue":"1","key":"10.1016\/j.virol.2025.110677_bib71","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12929-024-01030-9","article-title":"Dengue virus pathogenesis and host molecular machineries","volume":"31","author":"Sinha","year":"2024","journal-title":"J. Biomed. Sci."},{"issue":"6","key":"10.1016\/j.virol.2025.110677_bib72","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00873-13","article-title":"The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein","volume":"4","author":"Smith","year":"2013","journal-title":"mBio"},{"issue":"4","key":"10.1016\/j.virol.2025.110677_bib73","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1800820","article-title":"Effect of dengue serostatus on dengue vaccine safety and efficacy","volume":"379","author":"Sridhar","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virol.2025.110677_bib74","doi-asserted-by":"crossref","first-page":"12816","DOI":"10.1128\/JVI.00432-07","article-title":"Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes","volume":"81","author":"Sukupolvi-Petty","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2025.110677_bib75","doi-asserted-by":"crossref","first-page":"9227","DOI":"10.1128\/JVI.01087-10","article-title":"Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2","volume":"84","author":"Sukupolvi-Petty","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2025.110677_bib76","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3390\/ijms19010054","article-title":"Development of antibody therapeutics against flavivirus","volume":"19","author":"Sun","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.virol.2025.110677_bib77","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/22221751.2021.2021808","article-title":"Generation and characterization of genetically and antigenically diverse infectious clones of dengue virus serotypes 1-4","volume":"11","author":"Tamura","year":"2022","journal-title":"Emerg. Microb. Infect."},{"issue":"139","key":"10.1016\/j.virol.2025.110677_bib78","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003888","article-title":"The structural basis for serotype-specific neutralization of dengue virus by a human antibody","volume":"4","author":"Teoh","year":"2012","journal-title":"Sci. Transl. Med."},{"issue":"7","key":"10.1016\/j.virol.2025.110677_bib87","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): Checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.virol.2025.110677_bib79","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S1473-3099(09)70254-3","article-title":"Progress towards a dengue vaccine","volume":"9","author":"Webster","year":"2009","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.virol.2025.110677_bib81","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41541-016-0003-3","article-title":"A potent neutralizing antibody with therapeutic potential against all four serotypes of dengue virus","volume":"2","author":"Xu","year":"2017","journal-title":"NPJ Vaccines"},{"issue":"23","key":"10.1016\/j.virol.2025.110677_bib82","doi-asserted-by":"crossref","first-page":"12828","DOI":"10.1128\/JVI.01874-13","article-title":"A mouse monoclonal antibody against dengue virus type 1 Mochizuki strain targeting envelope protein domain II and displaying strongly neutralizing but not enhancing activity","volume":"87","author":"Yamanaka","year":"2013","journal-title":"J. Virol."},{"issue":"45","key":"10.1016\/j.virol.2025.110677_bib83","doi-asserted-by":"crossref","first-page":"6070","DOI":"10.1016\/j.vaccine.2015.07.089","article-title":"Expression of enhancing-activity-free neutralizing antibody against dengue type 1 virus in plasmid-inoculated mice","volume":"33","author":"Yamanaka","year":"2015","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.virol.2025.110677_bib84","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.chom.2020.04.007","article-title":"Identification of dengue virus serotype 3 specific antigenic sites targeted by neutralizing human antibodies","volume":"27","author":"Young","year":"2020","journal-title":"Cell Host Microbe"},{"issue":"11","key":"10.1016\/j.virol.2025.110677_bib85","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3390\/v9110338","article-title":"Structures and functions of the envelope glycoprotein in flavivirus infections","volume":"9","author":"Zhang","year":"2017","journal-title":"Viruses"},{"issue":"4","key":"10.1016\/j.virol.2025.110677_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107584","article-title":"A human antibody neutralizes different flaviviruses by using different mechanisms","volume":"31","author":"Zhang","year":"2020","journal-title":"Cell Rep."}],"updated-by":[{"DOI":"10.1016\/j.virol.2025.110696","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000}}],"container-title":["Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682225002910?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682225002910?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T08:38:41Z","timestamp":1780303121000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0042682225002910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":84,"alternative-id":["S0042682225002910"],"URL":"https:\/\/doi.org\/10.1016\/j.virol.2025.110677","relation":{},"ISSN":["0042-6822"],"issn-type":[{"value":"0042-6822","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neutralizing monoclonal antibodies against dengue virus: a scoping review of preclinical and clinical development","name":"articletitle","label":"Article Title"},{"value":"Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virol.2025.110677","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110677"}}